syros pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical r&d. central to the syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of syros' senior leadership. while this scientific approach has applications in many therapeutic areas, syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Company profile
Ticker
SYRS
Exchange
Website
CEO
Nancy Simonian
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LS22, Inc.
SEC CIK
Corporate docs
Subsidiaries
Syros Securities Corporation • Syros Pharmaceuticals (Ireland) Limited • Tyme Technologies, Inc. • Tyme, Inc. ...
SYRS stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
PRE 14A
Preliminary proxy
12 Apr 24
S-8
Registration of securities for employees
27 Mar 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
19 Dec 23
424B5
Prospectus supplement for primary offering
19 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
Transcripts
SYRS
Earnings call transcript
2023 Q3
14 Nov 23
SYRS
Earnings call transcript
2023 Q2
8 Aug 23
SYRS
Earnings call transcript
2023 Q1
10 May 23
SYRS
Earnings call transcript
2022 Q4
2 Mar 23
SYRS
Earnings call transcript
2022 Q3
14 Nov 22
SYRS
Earnings call transcript
2022 Q2
9 Aug 22
SYRS
Earnings call transcript
2022 Q1
16 May 22
SYRS
Earnings call transcript
2021 Q4
15 Mar 22
SYRS
Earnings call transcript
2021 Q3
5 Nov 21
SYRS
Earnings call transcript
2021 Q2
8 Aug 21
Latest ownership filings
4
David Roth
5 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
4
Kristin Stephens
2 Apr 24
4
Nancy A Simonian
2 Apr 24
4
David Roth
2 Apr 24
4
Gerald E Quirk
2 Apr 24
4
Jason Haas
2 Apr 24
4
Conley Chee
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
SC 13G
Blue Owl Capital Holdings LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 115.31 mm | 115.31 mm | 115.31 mm | 115.31 mm | 115.31 mm | 115.31 mm |
Cash burn (monthly) | 1.07 mm | 4.94 mm | 11.55 mm | 11.49 mm | 10.62 mm | 10.19 mm |
Cash used (since last report) | 7.39 mm | 34.00 mm | 79.41 mm | 79.01 mm | 73.04 mm | 70.06 mm |
Cash remaining | 107.92 mm | 81.31 mm | 35.90 mm | 36.30 mm | 42.26 mm | 45.25 mm |
Runway (months of cash) | 100.4 | 16.5 | 3.1 | 3.2 | 4.0 | 4.4 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 53 |
Opened positions | 4 |
Closed positions | 8 |
Increased positions | 13 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 40.97 bn |
Total shares | 18.75 mm |
Total puts | 0.00 |
Total calls | 79.90 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bain Capital Life Sciences Investors | 2.12 mm | $8.39 bn |
Bain Capital Life Sciences Fund II | 2.12 mm | $0.00 |
Samsara BioCapital | 1.59 mm | $0.00 |
Avidity Partners Management | 1.58 mm | $6.25 bn |
Artal | 1.48 mm | $5.83 mm |
Artal International S.C.A. | 1.46 mm | $0.00 |
Ally Bridge MedAlpha Master Fund | 1.44 mm | $0.00 |
CHI Advisors | 1.30 mm | $5.12 bn |
Flagship Pioneering | 993.85 k | $3.93 bn |
Samsara BioCapital | 881.45 k | $3.48 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | David Roth | Common Stock | Sell | Dispose S | No | Yes | 4.95 | 10,451 | 51.73 k | 0 |
2 Apr 24 | David Roth | Common Stock | Sell | Dispose S | No | Yes | 4.9803 | 150 | 747.05 | 10,451 |
1 Apr 24 | Conley Chee | Common Stock | Payment of exercise | Dispose F | No | No | 5.12 | 3,500 | 17.92 k | 22,504 |
1 Apr 24 | Jason Haas | Common Stock | Payment of exercise | Dispose F | No | No | 5.12 | 4,732 | 24.23 k | 24,552 |
1 Apr 24 | David Roth | Common Stock | Payment of exercise | Dispose F | No | No | 5.12 | 4,732 | 24.23 k | 10,601 |
1 Apr 24 | Kristin Stephens | Common Stock | Payment of exercise | Dispose F | No | No | 5.12 | 4,218 | 21.60 k | 25,237 |
31 Mar 24 | Conley Chee | Common Stock | Option exercise | Acquire M | No | No | 0 | 11,666 | 0.00 | 26,004 |
31 Mar 24 | Conley Chee | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,000 | 0.00 | 14,338 |
31 Mar 24 | Conley Chee | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 11,666 | 0.00 | 23,334 |
31 Mar 24 | Conley Chee | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,000 | 0.00 | 4,000 |
News
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
9 Apr 24
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
9 Apr 24
Piper Sandler Reiterates Overweight on Syros Pharmaceuticals, Maintains $13 Price Target
3 Apr 24
Top 3 Health Care Stocks You'll Regret Missing This Month
2 Apr 24
Press releases
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
9 Apr 24
Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
27 Mar 24
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
25 Mar 24
Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin?
2 Feb 24